Michael Ulz
Stock Analyst at Morgan Stanley
(3.80)
# 659
Out of 4,765 analysts
118
Total ratings
45.76%
Success rate
9.9%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michael Ulz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AARD Aardvark Therapeutics | Initiates: Overweight | $29 | $10.90 | +166.06% | 1 | Mar 10, 2025 | |
| YMAB Y-mAbs Therapeutics | Maintains: Underweight | $11 → $7 | $4.77 | +46.90% | 7 | Mar 5, 2025 | |
| SLN Silence Therapeutics | Maintains: Overweight | $49 → $45 | $4.06 | +1,008.37% | 11 | Mar 5, 2025 | |
| KPTI Karyopharm Therapeutics | Maintains: Outperform | $75 → $54 | $7.03 | +668.68% | 5 | Mar 3, 2025 | |
| IOVA Iovance Biotherapeutics | Maintains: Outperform | $24 → $20 | $3.53 | +467.38% | 4 | Feb 28, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Equal-Weight | $275 → $284 | $241.52 | +17.59% | 9 | Feb 14, 2025 | |
| THRD Third Harmonic Bio | Downgrades: Equal-Weight | $20 → $5 | $3.50 | +42.86% | 5 | Feb 12, 2025 | |
| GUTS Fractyl Health | Maintains: Overweight | $18 → $10 | $1.29 | +675.19% | 2 | Feb 3, 2025 | |
| AKRO Akero Therapeutics | Maintains: Overweight | $46 → $96 | $45.16 | +112.60% | 4 | Jan 28, 2025 | |
| VKTX Viking Therapeutics | Reiterates: Overweight | $105 | $30.59 | +243.22% | 2 | Sep 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $48 → $52 | $12.25 | +324.66% | 2 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $110 → $115 | $89.48 | +28.53% | 9 | Jul 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $53 → $57 | $45.48 | +25.33% | 3 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $36 → $27 | $15.49 | +74.31% | 4 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $40 | $2.51 | +1,493.56% | 1 | Mar 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $3 → $7 | $0.94 | +644.84% | 8 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $23 → $12 | $9.12 | +26.10% | 4 | Jan 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $25 | $1.82 | +1,273.63% | 5 | Nov 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $45 → $48 | $33.12 | +44.93% | 4 | Nov 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $27 | $7.85 | +243.95% | 2 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $30 → $20 | $3.15 | +534.92% | 3 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $8.66 | +419.93% | 1 | Feb 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $10 | $0.82 | +1,126.84% | 3 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $6 → $8 | $0.26 | +3,025.00% | 5 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $3 | $1.76 | +70.94% | 1 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $18 → $30 | $7.08 | +323.73% | 1 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $25 → $30 | $1.27 | +2,271.54% | 3 | Mar 30, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $45 | $7.37 | +511.00% | 1 | Oct 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $20 | $0.46 | +4,244.05% | 2 | May 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $85 → $80 | $39.70 | +101.54% | 3 | Nov 3, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $15 | $8.86 | +69.30% | 3 | Jul 12, 2017 |
Aardvark Therapeutics
Mar 10, 2025
Initiates: Overweight
Price Target: $29
Current: $10.90
Upside: +166.06%
Y-mAbs Therapeutics
Mar 5, 2025
Maintains: Underweight
Price Target: $11 → $7
Current: $4.77
Upside: +46.90%
Silence Therapeutics
Mar 5, 2025
Maintains: Overweight
Price Target: $49 → $45
Current: $4.06
Upside: +1,008.37%
Karyopharm Therapeutics
Mar 3, 2025
Maintains: Outperform
Price Target: $75 → $54
Current: $7.03
Upside: +668.68%
Iovance Biotherapeutics
Feb 28, 2025
Maintains: Outperform
Price Target: $24 → $20
Current: $3.53
Upside: +467.38%
Alnylam Pharmaceuticals
Feb 14, 2025
Maintains: Equal-Weight
Price Target: $275 → $284
Current: $241.52
Upside: +17.59%
Third Harmonic Bio
Feb 12, 2025
Downgrades: Equal-Weight
Price Target: $20 → $5
Current: $3.50
Upside: +42.86%
Fractyl Health
Feb 3, 2025
Maintains: Overweight
Price Target: $18 → $10
Current: $1.29
Upside: +675.19%
Akero Therapeutics
Jan 28, 2025
Maintains: Overweight
Price Target: $46 → $96
Current: $45.16
Upside: +112.60%
Viking Therapeutics
Sep 12, 2024
Reiterates: Overweight
Price Target: $105
Current: $30.59
Upside: +243.22%
Aug 14, 2024
Maintains: Overweight
Price Target: $48 → $52
Current: $12.25
Upside: +324.66%
Jul 12, 2024
Maintains: Equal-Weight
Price Target: $110 → $115
Current: $89.48
Upside: +28.53%
Jun 18, 2024
Maintains: Overweight
Price Target: $53 → $57
Current: $45.48
Upside: +25.33%
May 13, 2024
Maintains: Equal-Weight
Price Target: $36 → $27
Current: $15.49
Upside: +74.31%
Mar 4, 2024
Initiates: Overweight
Price Target: $40
Current: $2.51
Upside: +1,493.56%
Feb 27, 2024
Maintains: Equal-Weight
Price Target: $3 → $7
Current: $0.94
Upside: +644.84%
Jan 5, 2024
Downgrades: Underweight
Price Target: $23 → $12
Current: $9.12
Upside: +26.10%
Nov 29, 2023
Maintains: Overweight
Price Target: $28 → $25
Current: $1.82
Upside: +1,273.63%
Nov 3, 2023
Maintains: Equal-Weight
Price Target: $45 → $48
Current: $33.12
Upside: +44.93%
Aug 16, 2023
Maintains: Outperform
Price Target: $15 → $27
Current: $7.85
Upside: +243.95%
Mar 24, 2023
Maintains: Equal-Weight
Price Target: $30 → $20
Current: $3.15
Upside: +534.92%
Feb 1, 2023
Initiates: Overweight
Price Target: $45
Current: $8.66
Upside: +419.93%
Jan 27, 2023
Maintains: Overweight
Price Target: $20 → $10
Current: $0.82
Upside: +1,126.84%
Jan 27, 2023
Maintains: Equal-Weight
Price Target: $6 → $8
Current: $0.26
Upside: +3,025.00%
Jan 27, 2023
Downgrades: Equal-Weight
Price Target: $3
Current: $1.76
Upside: +70.94%
Jan 27, 2023
Upgrades: Equal-Weight
Price Target: $18 → $30
Current: $7.08
Upside: +323.73%
Mar 30, 2022
Maintains: Equal-Weight
Price Target: $25 → $30
Current: $1.27
Upside: +2,271.54%
Oct 8, 2020
Initiates: Outperform
Price Target: $45
Current: $7.37
Upside: +511.00%
May 28, 2020
Maintains: Outperform
Price Target: $12 → $20
Current: $0.46
Upside: +4,244.05%
Nov 3, 2017
Maintains: Outperform
Price Target: $85 → $80
Current: $39.70
Upside: +101.54%
Jul 12, 2017
Maintains: Outperform
Price Target: $12 → $15
Current: $8.86
Upside: +69.30%